Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

V. Soukup, M. Kalousová, O. Capoun, R. Sobotka, Z. Breyl, M. Pešl, T. Zima, T. Hanuš,

. 2015 ; 95 (1) : 56-64. [pub] 20150206

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

OBJECTIVES: To determine the combination of urinary protein markers for noninvasive detection of primary and recurrent urothelial bladder carcinomas. METHODS: Urinary concentrations of 27 biomarkers (NSE, ATT, AFABP, Resistin, Midkine, Clusterin, Uromodulin, ZAG2, HSP27, HSP 60, NCAM1/CD56, Angiogenin, Calreticulin, Chromogranin A, CEACAM1, CXCL1, IL13Ra2, Progranulin, VEGFA, CarbAnhydIX, Annexin-V, TIM4, Galectin1, Cystatin B, Synuclein G, ApoA1 and ApoA2) were assessed by enzyme-linked immunosorbent assay or by electrochemiluminiscence immunoassay. RESULTS: During the primary diagnostics, a group of 70 patients with primary occurrence of bladder cancer and 49 healthy control subjects were compared. For this clinical situation, the most accurate combination proved to be the combination of cytology with markers Midkine and Synuclein G (sensitivity 91.8%, specificity 97.5%). During the monitoring of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared with the group of 61 patients with a history of NMIBC without current disease. For this clinical situation, the most accurate combination proved to be the combination of cytology and erythrocytes count in urine sediment with markers Midkine, ZAG2, CEACAM1, and Synuclein G (sensitivity 92.68%, specificity 90.16%). A lower accuracy of the diagnostic panel and the necessity to use more markers in the case of recurrence was connected with a different structure of patients. CONCLUSIONS: Multi-marker test can significantly improve the bladder cancer detection both during the primary diagnostics and monitoring of patients with NMIBC. This outcome should result in other, larger studies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020976
003      
CZ-PrNML
005      
20160728122808.0
007      
ta
008      
160722s2015 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000368166 $2 doi
024    7_
$a 10.1159/000368166 $2 doi
035    __
$a (PubMed)25662337
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Soukup, Viktor $u Department of Urology, General University Hospital and The First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
245    10
$a Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma / $c V. Soukup, M. Kalousová, O. Capoun, R. Sobotka, Z. Breyl, M. Pešl, T. Zima, T. Hanuš,
520    9_
$a OBJECTIVES: To determine the combination of urinary protein markers for noninvasive detection of primary and recurrent urothelial bladder carcinomas. METHODS: Urinary concentrations of 27 biomarkers (NSE, ATT, AFABP, Resistin, Midkine, Clusterin, Uromodulin, ZAG2, HSP27, HSP 60, NCAM1/CD56, Angiogenin, Calreticulin, Chromogranin A, CEACAM1, CXCL1, IL13Ra2, Progranulin, VEGFA, CarbAnhydIX, Annexin-V, TIM4, Galectin1, Cystatin B, Synuclein G, ApoA1 and ApoA2) were assessed by enzyme-linked immunosorbent assay or by electrochemiluminiscence immunoassay. RESULTS: During the primary diagnostics, a group of 70 patients with primary occurrence of bladder cancer and 49 healthy control subjects were compared. For this clinical situation, the most accurate combination proved to be the combination of cytology with markers Midkine and Synuclein G (sensitivity 91.8%, specificity 97.5%). During the monitoring of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared with the group of 61 patients with a history of NMIBC without current disease. For this clinical situation, the most accurate combination proved to be the combination of cytology and erythrocytes count in urine sediment with markers Midkine, ZAG2, CEACAM1, and Synuclein G (sensitivity 92.68%, specificity 90.16%). A lower accuracy of the diagnostic panel and the necessity to use more markers in the case of recurrence was connected with a different structure of patients. CONCLUSIONS: Multi-marker test can significantly improve the bladder cancer detection both during the primary diagnostics and monitoring of patients with NMIBC. This outcome should result in other, larger studies.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x moč $7 D014408
650    _2
$a karcinom $x diagnóza $x moč $7 D002277
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a elektrochemie $7 D004563
650    _2
$a ELISA $7 D004797
650    _2
$a falešně pozitivní reakce $7 D005189
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a luminiscence $7 D049449
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a lokální recidiva nádoru $x diagnóza $x moč $7 D009364
650    _2
$a neurotrofní faktory $x metabolismus $7 D009414
650    _2
$a ROC křivka $7 D012372
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a nádory močového měchýře $x diagnóza $x moč $7 D001749
650    _2
$a močové ústrojí $x patologie $7 D014551
650    _2
$a gama-synuklein $x metabolismus $7 D051845
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kalousová, Marta
700    1_
$a Capoun, Otakar
700    1_
$a Sobotka, Roman
700    1_
$a Breyl, Zuzana
700    1_
$a Pešl, Michael
700    1_
$a Zima, Tomas
700    1_
$a Hanuš, Tomáš
773    0_
$w MED00004616 $t Urologia internationalis $x 1423-0399 $g Roč. 95, č. 1 (2015), s. 56-64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25662337 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160728123030 $b ABA008
999    __
$a ok $b bmc $g 1155646 $s 945504
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 95 $c 1 $d 56-64 $e 20150206 $i 1423-0399 $m Urologia internationalis $n Urol Int $x MED00004616
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...